The Saltiel laboratory investigates the molecular events involved in the regulation of glucose uptake and storage, with special attention to mechanisms underlying the specificity of the actions of insulin and the links between obesity and diabetes.
Developing new drugs targeting defects in the uptake and storage of glucose in muscle and fat cells requires a better grasp of the cell biology of insulin action. Read More
The banner image above is from Xiao-Wei Chen, Dara Leto, Junyu Xiao ... and Alan R. Saltiel: Exocyst function regulated by effector phosphorylation. Nat Cell Biol. 2011 May; 13(5): 580–588.
About Dr. Alan Saltiel
Dr. Alan R. Saltiel is a cell biologist who researches the hormone insulin and how it relates to obesity, diabetes and other metabolic disorders.
He holds 18 patents, has published more than 280 original papers and developed drugs for diabetes and cancer. He is ranked 18th among the most highly cited authors in biology and biochemistry over the past decade.
Amlexanox, an off-patent drug, also reverses obesity, diabetes and fatty liver in mice by inhibiting two genes—IKKE and TBK1—that together act as a sort of brake on metabolism. By releasing the brake, amlexanox seems to free the metabolic system to burn more, and possibly store less, energy.
The research was published in Nature Medicine. Read More